OUR STORY
“Cancer treatment is sadly too often unsuccessful. The challenge lies in striking a delicate balance - finding treatments more harmful to cancer cells than healthy ones. Now, for the first time, we can target tumors where platinum-based treatments are effective .”
- Peter Buhl Jensen, CEO
In 2022, CHOSA Oncology was founded by the very team that had pioneered LiPlaCis. Backed by decades of experience in oncology and biotechnology, we are committed to advancing cancer treatment. Our merger with RhoVac AB in the same year enabled us to expand our reach and impact globally.
Founding CHOSA
Starting with LiPlaCis®
Our story started with the development of LiPlaCis®, a breakthrough in cancer treatment that emerged from a collaboration between the Danish Technical University and the University of Copenhagen. Designed to enhance the efficacy of cisplatin while reducing its toxicity, LiPlaCis represents a leap forward in personalized cancer care
Innovation with DRP®
Our Drug Response Predictor (DRP®) is a breakthrough technology that identifies patients who will respond best to platin-based treatments, enabling a truly personalized approach to cancer care. By tailoring treatment to each patient's biology, we can improve outcomes and advance precision medicine. This approach also allows doctors to avoid giving cisplatin to non-responders, sparing them side effects and ensuring they can access potentially more effective treatments without delay.
Our Global Presence
While our main office is located in Medicon Village in Lund, Sweden, we are proud to be part of the thriving biotech ecosystem at the BioInnovation Institute (BII) in Copenhagen, Denmark. This dual presence allows us to harness the best of Scandinavian innovation and research in oncology.
Looking to the Future
We continue transforming cancer care through smarter, more targeted treatments. We remain dedicated to improving outcomes for patients worldwide and believe that by combining cutting-edge science with compassion, we can make a profound difference.
Take a look at our CEO, Peter Buhl Jensen, explaining CHOSA’s role in the cancer-treatment market, in context with ESMO 2024.
Take a look for yourself…
Meet the team
Our team is dedicated to advancing cancer care with compassion, innovation, and expertise. Each member of our team brings specialized knowledge and a shared commitment to improving patient outcomes and supporting our partners in oncology.
